Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates

被引:7
作者
Catalano, Antonino [1 ]
Vita, Gian Luca [2 ]
Bellone, Federica [1 ]
Sframeli, Maria [1 ,2 ]
Distefano, Maria Grazia [1 ]
La Rosa, Matteo [1 ]
Gaudio, Agostino [3 ]
Vita, Giuseppe [1 ,2 ]
Morabito, Nunziata [1 ]
Messina, Sonia [1 ,2 ]
机构
[1] Univ Messina, Dept Clin & Expt Med, AOU Policlin G Martino, Via C Valeria, I-98125 Messina, Italy
[2] Univ Hosp G Martino, Aurora Onlus Fdn, Nemo Sud Clin Ctr Neuromuscular Disorders, Messina, Italy
[3] Univ Catania, Dept Clin & Expt Med, Catania, Italy
关键词
Duchenne muscular dystrophy; Bone mineral density; Bone turnover; Sclerostin; Forced vital capacity; Left ventricular ejection fraction; Glucocorticoid; Fractures; QUALITY-OF-LIFE; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; SCLEROSTIN SERUM-LEVELS; MINERAL DENSITY; VERTEBRAL FRACTURES; PATHOPHYSIOLOGY; WOMEN; BOYS; METABOLISM; EXPERIENCE;
D O I
10.1007/s40618-021-01676-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose An increased fracture risk is commonly reported in Duchenne muscular dystrophy (DMD). Our aim was to investigate bone mineral density (BMD) and bone turnover, including sclerostin, and their association with markers of cardiac and respiratory performance in a cohort of DMD subjects. Methods In this single center, cross sectional observational study, lumbar spine (LS) BMD Z-scores, C-terminal telopeptide of procollagen type I (CTX) and osteocalcin (BGP), as bone resorption and formation markers, respectively, and sclerostin were assessed. Left ventricular ejection fraction (LVEF) and forced vital capacity (FVC) were evaluated. Clinical prevalent fractures were also recorded. Results Thirty-one patients [median age = 14 (12-21.5) years] were studied. Ambulant subjects had higher LS BMD Z-scores compared with non-ambulant ones and subjects with prevalent clinical fractures [n = 9 (29%)] showed lower LS BMD Z-scores compared with subjects without fractures. LS BMD Z-scores were positively correlated with FVC (r = 0.50; p = 0.01), but not with glucocorticoid use, and FVC was positively associated with BGP (r = 0.55; p = 0.02). In non-ambulant subjects, LS BMD Z-scores were associated with BMI (r = 0.54; p = 0.02) and sclerostin was associated with age (r = 0.44; p = 0.05). Age, BMI, FVC and sclerostin were independently associated with LS BMD Z-score in a stepwise multiple regression analysis. Older age, lower BMI, FVC and sclerostin were associated with lower LS BMD Z-scores. Conclusion In a cohort of DMD patients, our data confirm low LS BMD Z-scores, mainly in non-ambulant subjects and irrespective of the glucocorticoid use, and suggest that FVC and sclerostin are independently associated with LS BMD Z-scores.
引用
收藏
页码:517 / 525
页数:9
相关论文
共 62 条
[1]   Evaluating RANKL and OPG levels in patients with Duchenne muscular dystrophy [J].
Ali, S. Akhtar ;
Kang, H. ;
Olney, R. ;
Ramos-Platt, L. ;
Ryabets-Lienhard, A. ;
Cheung, C. ;
Georgia, S. ;
Pitukcheewanont, P. .
OSTEOPOROSIS INTERNATIONAL, 2019, 30 (11) :2283-2288
[2]   Sclerostin Inhibition in the Management of Osteoporosis [J].
Appelman-Dijkstra, Natasha M. ;
Papapoulos, Socrates E. .
CALCIFIED TISSUE INTERNATIONAL, 2016, 98 (04) :370-380
[3]   Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy [J].
Bell, Jennifer M. ;
Shields, Michael D. ;
Watters, Janet ;
Hamilton, Alistair ;
Beringer, Timothy ;
Elliott, Mark ;
Quinlivan, Rosaline ;
Tirupathi, Sandya ;
Blackwood, Bronagh .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (01)
[4]  
Bian Q., 2019, GLOB PEDIAT HLTH, DOI 10.1177/2333794X19835661
[5]   Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment [J].
Bianchi, M. L. ;
Morandi, L. ;
Andreucci, E. ;
Vai, S. ;
Frasunkiewicz, J. ;
Cottafava, R. .
OSTEOPOROSIS INTERNATIONAL, 2011, 22 (02) :529-539
[6]   Bone Health in Children and Adolescents With Chronic Diseases That May Affect the Skeleton: The 2013 ISCD Pediatric Official Positions [J].
Bianchi, Maria Luisa ;
Leonard, Mary B. ;
Bechtold, Susanne ;
Hoegler, Wolfgang ;
Mughal, M. Zulf ;
Schoenau, Eckhart ;
Sylvester, Francisco A. ;
Vogiatzi, Maria ;
van den Heuvel-Eibrink, Marry M. ;
Ward, Leanne .
JOURNAL OF CLINICAL DENSITOMETRY, 2014, 17 (02) :281-294
[7]   Bone mineral density and bone metabolism in Duchenne muscular dystrophy [J].
Bianchi, ML ;
Mazzanti, A ;
Galbiati, E ;
Saraifoger, S ;
Dubini, A ;
Cornelio, F ;
Morandi, L .
OSTEOPOROSIS INTERNATIONAL, 2003, 14 (09) :761-767
[8]   Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management [J].
Birnkrant, David J. ;
Bushby, Katharine ;
Bann, Carla M. ;
Alman, Benjamin A. ;
Apkon, Susan D. ;
Blackwell, Angela ;
Case, Laura E. ;
Cripe, Linda ;
Hadjiyannakis, Stasia ;
Olson, Aaron K. ;
Sheehan, Daniel W. ;
Bolen, Julie ;
Weber, David R. ;
Ward, Leanne M. .
LANCET NEUROLOGY, 2018, 17 (04) :347-361
[9]   Optimizing Bone Health in Duchenne Muscular Dystrophy [J].
Buckner, Jason L. ;
Bowden, Sasigarn A. ;
Mahan, John D. .
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
[10]   Perspectives on osteoporosis therapies [J].
Cairoli, E. ;
Zhukouskaya, V. V. ;
Eller-Vainicher, C. ;
Chiodini, I. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2015, 38 (03) :303-311